Figure 2.
HRs of event rates for sodium-glucose co-transporter-2 therapies versus empagliflozin. (A) canagliflozin versus empagliflozin, (B) dapagliflozin versus empagliflozin. Studies included in the indirect treatment comparison: EMPA-REG OUTCOME, CANVAS Program, and DECLARE-TIMI 58. CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure; ITT, intent-to-treat; MI, myocardial infarction.